Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains
Section snippets
Acknowledgements
This work was supported by a New Zealand Health Research Council Programme Grant, by the New Zealand Neurological Foundation and by the National Research Centre for Growth and Development. We thank the Neurological Foundation of New Zealand Human Brain Bank for providing the human brain tissue and the Biomedical Imaging Research Unit of The University of Auckland for their excellent expertise.
References (46)
- et al.
Increased immunoreactivity for Jun- and Fos-related proteins in Alzheimer's disease: association with pathology
Exp. Neurol.
(1994) - et al.
The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1
Cell
(1988) - et al.
c-Jun promotes neurite outgrowth and survival in PC12 cells
Brain Res. Mol. Brain Res.
(2000) Tau protein and the neurofibrillary pathology of Alzheimer's disease
Trends Neurosci.
(1993)- et al.
JNK-dependent phosphorylation of c-Jun on Serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells
J. Biol. Chem.
(2004) - et al.
Expression of Fos, Jun, and Krox family proteins in Alzheimer's disease
Exp. Neurol.
(1997) - et al.
Activating transcription factor 2 expression in the adult human brain: association with both neurodegeneration and neurogenesis
Neuroscience
(2005) - et al.
Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease
Brain Res. Mol. Brain Res.
(2002) - et al.
The AP-1 Transcription Factor c-Jun Is Required for Efficient Axonal Regeneration
Neuron
(2004) - et al.
Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4
Exp. Cell. Res.
(1998)
c-Jun controls the efficiency of MAP kinase signaling by transcriptional repression of MAP kinase phosphatases
Exp. Cell. Res.
(2005)
p38 MAP kinase is activated at early stages in Alzheimer's disease brain
Exp. Neurol.
(2003)
PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus
Exp. Neurol.
(2001)
c-fos protein-like immunoreactivity: distribution in the human brain and over-expression in the hippocampus of patients with Alzheimer's disease
Neuroscience
(1992)
Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a caspase cascade and JNK1
J. Biol. Chem.
(2003)
Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells
J. Mol. Biol.
(2002)
Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis
Mech. Ageing Dev.
(2001)
DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay
J. Neurosci.
(1996)
Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis
J. Neuropathol. Exp. Neurol.
(2001)
Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression
EMBO J.
(2000)
Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain
Nature
(1991)
Transcriptional activation by the v-Jun oncoprotein is independent of positive regulatory phosphorylation
Oncogene
(1994)
Neuropathological stageing of Alzheimer-related changes
Acta Neuropathol. (Berl)
(1991)
Cited by (0)
Copyright © 2006 Elsevier Ireland Ltd. All rights reserved.